Emerald Advisers LLC Decreases Stock Position in Horizon Therapeutics PLC (NASDAQ:HZNP)

Share on StockTwits

Emerald Advisers LLC lessened its stake in Horizon Therapeutics PLC (NASDAQ:HZNP) by 7.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,207,559 shares of the biopharmaceutical company’s stock after selling 103,519 shares during the quarter. Horizon Therapeutics comprises about 1.5% of Emerald Advisers LLC’s holdings, making the stock its 16th largest holding. Emerald Advisers LLC’s holdings in Horizon Therapeutics were worth $32,882,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HZNP. Nuveen Asset Management LLC boosted its holdings in Horizon Therapeutics by 1,910.0% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock worth $40,249,000 after acquiring an additional 1,589,614 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Horizon Therapeutics by 1,774.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock worth $26,508,000 after acquiring an additional 1,042,969 shares during the period. Rhenman & Partners Asset Management AB purchased a new position in Horizon Therapeutics in the 3rd quarter worth approximately $27,911,000. Renaissance Technologies LLC boosted its holdings in Horizon Therapeutics by 11.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock worth $210,628,000 after acquiring an additional 896,500 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its holdings in Horizon Therapeutics by 15.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 5,097,929 shares of the biopharmaceutical company’s stock worth $122,656,000 after acquiring an additional 695,950 shares during the period. Hedge funds and other institutional investors own 86.86% of the company’s stock.

HZNP has been the subject of a number of analyst reports. Zacks Investment Research cut Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price target for the company. in a report on Tuesday, October 29th. Piper Jaffray Companies set a $33.00 price target on Horizon Therapeutics and gave the stock a “buy” rating in a report on Monday, August 26th. Bank of America initiated coverage on Horizon Therapeutics in a report on Thursday, September 26th. They issued a “buy” rating and a $34.00 price target for the company. ValuEngine cut Horizon Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 5th. Finally, BidaskClub upgraded Horizon Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $33.46.

Horizon Therapeutics stock opened at $29.52 on Friday. Horizon Therapeutics PLC has a 52 week low of $17.94 and a 52 week high of $29.85. The company has a current ratio of 2.20, a quick ratio of 2.12 and a debt-to-equity ratio of 0.90. The stock has a 50 day moving average of $27.35 and a 200-day moving average of $25.82. The stock has a market cap of $5.39 billion, a P/E ratio of 16.13, a price-to-earnings-growth ratio of 1.71 and a beta of 0.83.

Horizon Therapeutics (NASDAQ:HZNP) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.14. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The firm had revenue of $320.60 million for the quarter, compared to analyst estimates of $296.27 million. During the same period last year, the company earned $0.48 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. As a group, equities analysts predict that Horizon Therapeutics PLC will post 1.58 earnings per share for the current fiscal year.

In other news, CEO Timothy P. Walbert sold 320,174 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $28.02, for a total transaction of $8,971,275.48. Following the transaction, the chief executive officer now directly owns 892,483 shares of the company’s stock, valued at $25,007,373.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeff Kent sold 11,140 shares of the firm’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $23.84, for a total value of $265,577.60. Following the transaction, the insider now directly owns 127,115 shares in the company, valued at $3,030,421.60. The disclosure for this sale can be found here. Insiders have sold 595,679 shares of company stock worth $16,564,964 over the last three months. Corporate insiders own 4.10% of the company’s stock.

Horizon Therapeutics Profile

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Article: What are the components of an earnings report?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ted Baker’s  “Under Review” Rating Reaffirmed at Panmure Gordon
Ted Baker’s “Under Review” Rating Reaffirmed at Panmure Gordon
SSE  Receives Neutral Rating from UBS Group
SSE Receives Neutral Rating from UBS Group
RSA Insurance Group  Receives “Outperform” Rating from Royal Bank of Canada
RSA Insurance Group Receives “Outperform” Rating from Royal Bank of Canada
WPP  Price Target Lowered to GBX 1,100 at JPMorgan Chase & Co.
WPP Price Target Lowered to GBX 1,100 at JPMorgan Chase & Co.
FedoraCoin  Price Up 10.9% Over Last Week
FedoraCoin Price Up 10.9% Over Last Week
Alphacat Market Capitalization Tops $479,604.00
Alphacat Market Capitalization Tops $479,604.00


© 2006-2019 Ticker Report